Chrissy Metz discloses GLP-1 use and joins Ro

Actress Chrissy Metz, best known for the NBC drama This Is Us, has said publicly that she takes a GLP-1 medication after years of skepticism, and she has signed on as a brand ambassador for the digital health company Ro ^[1].

Metz, now 45, told People magazine that she had assumed for a long time that the drugs either would not work for her or that side effects would make them unbearable. She said the onset of perimenopause changed her thinking ^[1].

"I'm not getting any younger," Metz told the magazine. "There were obesity issues within my family and with my father, and I felt like I've tried so many modalities, whether it was diets or therapy, and none of it really worked for me" ^[1].

She described the change in her relationship with food in terms many patients use — the quieting of constant thoughts about eating. "It's so nice not to be obsessing about what I'm going to have [to eat] every minute, even as I'm still consuming the meal," she said. "I vilified food for so long because I was taught that it was bad, and you shouldn't eat this or that. And it's been helping me be more mobile and have less joint pain and inflammation" ^[1].

What the coverage does not say

The published account does not name which GLP-1 medication Metz takes, does not give a dose, and does not say how long she has been on treatment ^[1]. A photo caption accompanying the coverage references a 100-pound weight loss, but the article text itself does not detail the amount or the timeline ^[1]. Financial terms of her arrangement with Ro were not disclosed in the source material ^[1].

Metz is not the first celebrity Ro has signed. Tennis champion Serena Williams disclosed in 2025 that she lost 31 pounds using Zepbound (tirzepatide) after her second child, and she is a paid Ro ambassador who has said that using a weight loss drug "isn't a shortcut, it's healthcare" ^[1]. Other companies have done the same: Rebel Wilson is chief wellness officer at Noom, and Shaquille O'Neal said in June 2026 that he takes Zepbound for moderate obstructive sleep apnea while partnering with the drug's maker, Eli Lilly ^[1].

Why it matters for patients

Celebrity disclosures cut two ways. On one hand, they make it easier to talk openly about obesity treatment instead of treating weight as a personal failing — the same point Whoopi Goldberg made when she said, "Maybe the key is to stop judging everybody" ^[1]. On the other hand, a paid ambassadorship is advertising. When a public figure's story appears alongside a telehealth brand, the message is shaped in part by a company that sells access to prescriptions.

The details that matter most for an individual decision are usually the ones missing from these stories: which drug, at what dose, with what side effects, at what cost, and for how long. Metz's account, as published, includes none of that ^[1].

One widely reported celebrity experience does address durability. Oprah Winfrey told People in December 2025 that she stopped her GLP-1 about six months in to see whether she could "beat the medication," then regained roughly 20 pounds over the next 12 months. "It's going to be a lifetime thing," she said, comparing it to her blood pressure medication. "I've proven to myself I need it" ^[1].

Individual results in these accounts also vary widely — Charles Barkley said he went from 352 to 290 pounds on Mounjaro (tirzepatide) ^[1], while Williams reported 31 pounds on Zepbound ^[1] and Kathy Bates said Ozempic (semaglutide) accounted for the final 20 pounds of a 100-pound loss achieved mostly through lifestyle changes ^[1]. None of those figures predict what any other person would experience.

What happens next

Metz's interview was published in early August 2026, and the roundup citing it was updated August 11, 2026 ^[1]. The sources do not say what form her Ro campaign will take, how long it will run, or whether she will disclose more about her treatment. Those details are not yet known.